Dapagliflozin

Generic Name: Dapagliflozin

Brand Names: Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClO_₆

CAS Number: 461432-26-8

Unique Ingredient Identifier: 1ULL0QJ8UC

Background: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...

Indication: Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure

Associated Therapies: -

Clinical Trials

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Dapagliflozin
Other: Placebo for dapagliflozin

First Posted Date: 2015-06-03

Last Posted Date: 2019-03-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 815

Registration Number: NCT02460978

Locations: 🇬🇧
Research Site, Wakefield, United Kingdom

Effect of Dapagliflozin on Glycemic Variability

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2015-06-02

Last Posted Date: 2017-07-13

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 86

Registration Number: NCT02459353

Locations: 🇰🇷
Seoul St.Mary's Hospital, Seoul, Korea, Republic of

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: dapagliflozin

First Posted Date: 2015-05-05

Last Posted Date: 2019-10-30

Lead Sponsor: University at Buffalo

Target Recruit Count: 52

Registration Number: NCT02433678

Locations: 🇺🇸
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Phase 4

Completed

Conditions: Type II Diabetes

Interventions: Drug: Placebo
Drug: Farxiga
Drug: Metformin
Drug: Insulin

First Posted Date: 2015-04-29

Last Posted Date: 2017-06-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 226

Registration Number: NCT02429258

Locations: 🇺🇸
Research Site, Renton, Washington, United States

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2015-04-27

Last Posted Date: 2018-02-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 55

Registration Number: NCT02426541

Locations: 🇫🇮
Research Site, Turku, Finland

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Phase 3

Completed

Conditions: Diabetes

Interventions: Drug: Saxagliptin
Drug: Glimepiride
Drug: Dapagliflozin
Other: Placebo

First Posted Date: 2015-04-17

Last Posted Date: 2020-06-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 444

Registration Number: NCT02419612

Locations: 🇬🇧
Research Site, Dundee, United Kingdom

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Dapagliflozin

First Posted Date: 2015-04-17

Last Posted Date: 2016-04-21

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 30

Registration Number: NCT02420392

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

Phase 4

Completed

Conditions: Diabetes
Heart Failure

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2015-03-25

Last Posted Date: 2018-07-31

Lead Sponsor: University of Dundee

Target Recruit Count: 56

Registration Number: NCT02397421

Locations: 🇬🇧
Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom

Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2015-03-09

Last Posted Date: 2018-05-11

Lead Sponsor: University of Erlangen-Nürnberg Medical School

Target Recruit Count: 59

Registration Number: NCT02383238

Locations: 🇩🇪
University Erlangen-Nuernberg, Erlangen, Germany

Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

Phase 4

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: glimpiride
Drug: dapagliflozin

First Posted Date: 2015-02-26

Last Posted Date: 2015-02-26

Lead Sponsor: Gulf Regional Research & Educational Services, LLC

Target Recruit Count: 21

Registration Number: NCT02372955

Locations: 🇺🇸
Gulf Regional Research & Educational Services, LLC, Metairie, Louisiana, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy